Long-term safety and efficacy study of a medical device containing xyloglucan, pea protein reticulated with tannins and xylo-oligosaccharides, in patients with diarrhoea-predominant irritable bowel syndrome.

Constanza Ciriza de Los RiosBlanca Serrano FalcónFederico Arguelles-AriasEsperanza PérezCarlos TeruelFernando GeijoEnrique Rey

Published in: Therapeutic advances in gastroenterology (2021)

Treating IBS-D patients with XG-PPT-XOS is effective and safe in the long term within a clinical setting, improving all IBS-D symptoms from the first month of treatment and showing a sustained response over the term of therapy.

Keyphrases

irritable bowel syndrome
healthcare
preterm infants
stem cells
protein protein
depressive symptoms
gestational age
mesenchymal stem cells
sleep quality